Laura Korthauer

Dr. Laura Korthauer

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in NeuroImage
Verified
Journal Article
Closed access
LKLaura Korthauer
Laura Korthauer
LZL. Zhan
L. Zhan
OAO. Ajilore
O. Ajilore
ALA. Leow
A. Leow
IDI. Driscoll
I. Driscoll

3 November 2020 in Cerebral Cortex
Verified
Journal Article
Open access
PDF file
IFIgor Fortel
Igor Fortel
LKLaura Korthauer
Laura Korthauer
ZMZachery Morrissey
Zachery Morrissey
LZLiang Zhan
Liang Zhan
OAOlusola Ajilore
Olusola Ajilore
ALAlex Leow
Alex Leow
Synaptic dysfunction is hypothesized to be one of the earliest brain changes in Alzheimer’s disease, leading to “hyperexcitability” in neuronal circuits. In this study, we evaluated a novel hyperexcitation indicator (HI) for each brain region using a hybrid resting-state structural connectome to probe connectome-level excitation–inhibition balance in cognitively intact middle-aged apolipoprotein E (APOE) ε4 carriers with noncarriers (16 male/22 female in each group). Regression with three-way interactions (sex, age, and APOE-ε4 carrier status) to assess the effect of APOE-ε4 on excitation–inhibition balance within each sex and across an age range of 40–60 years yielded a significant shift toward higher HI in female carriers compared with noncarriers (beginning at 50 years). Hyperexcitation was insignificant in the male group. Further, in female carriers the degree of hyperexcitation exhibited significant positive correlation with working memory performance (evaluated via a virtual Morris Water task) in three regions: the left pars triangularis, left hippocampus, and left isthmus of cingulate gyrus. Increased excitation of memory-related circuits may be evidence of compensatory recruitment of neuronal resources for memory-focused activities. In sum, our results are consistent with known Alzheimer’s disease sex differences; in that female APOE-ε4 carriers have globally disrupted excitation–inhibition balance that may confer greater vulnerability to disease neuropathology.

11 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LKLaura Korthauer
Laura Korthauer
RGRobert P. Giugliano
Robert P. Giugliano
JGJianping Guo
Jianping Guo
MSMarc S. Sabatine
Marc S. Sabatine
PSPeter Sever
Peter Sever
BOBrian R. Ott
Brian R. Ott
APOE encodes a cholesterol transporter, and the ε4 allele is associated with higher circulating cholesterol levels, ß-amyloid burden, and risk of Alzheimer’s disease. Prior studies demonstrated no significant differences in objective or subjective cognitive function for patients receiving the PCSK9 inhibitor evolocumab vs. placebo added to statin therapy. There is some evidence that cholesterol-lowering medications may confer greater cognitive benefits in APOE ε4 carriers. Thus, the purpose of this study was to determine whether APOE genotype moderates the relationships between evolocumab use and cognitive function. APOE-genotyped patients (N = 13,481; 28% ε4 carriers) from FOURIER, a randomized, placebo-controlled trial of evolocumab added to statin therapy in patients with stable atherosclerotic cardiovascular disease followed for a median of 2.2 years, completed the Everyday Cognition Scale (ECog) to self-report cognitive changes from the end of the trial compared to its beginning; a subset (N = 835) underwent objective cognitive testing using the Cambridge Neuropsychological Test Automated Battery as part of the EBBINGHAUS trial. There was a dose-dependent relationship between APOE ε4 genotype and patient-reported memory decline on the ECog in the placebo arm (p = .003 for trend across genotypes; ε4/ε4 carriers vs. non-carriers: OR = 1.46, 95% CI [1.03, 2.08]) but not in the evolocumab arm (p = .50, OR = 1.18, 95% CI [.83,1.66]). However, the genotype by treatment interaction was not significant (p = .30). In the subset of participants who underwent objective cognitive testing with the CANTAB, APOE genotype did not significantly modify the relationship between treatment arm and CANTAB performance after adjustment for demographic and medical covariates, (p’s>.05). Although analyses were limited by the low population frequency of the ε4/ε4 genotype, this supports the cognitive safety of evolocumab among ε4 carriers, guiding future research on possible benefits of cholesterol-lowering medications in people at genetic risk for Alzheimer’s disease.

13 May 2024 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
JZJessica J. Zakrzewski
Jessica J. Zakrzewski
JDJennifer D. Davis
Jennifer D. Davis
ZGZachary T. Gemelli
Zachary T. Gemelli
LKLaura Korthauer
Laura Korthauer
Background: There are significant public health benefits to delaying the onset of Alzheimer’s disease (AD) in individuals at risk. However, adherence to brain healthy behaviors is low. The Health Belief Model proposes that specific beliefs are mediators of behavior change. Objective: To characterize health belief measures from the Science of Behavior Change Research Network (SBCRN) in an older adult population and associations between health beliefs, AD risk, and current health behaviors. Methods: A total of 172 individuals from the Rhode Island AD Prevention Registry participated. SBCRN health belief measures included assessments of future time perspective, self-efficacy, deferment of gratification, and consideration of future consequences. Outcome measures included individual AD risk index score, dementia risk awareness, and lifestyle behaviors including physical, cognitive, and social activity. Results: Participants who were older had higher scores for AD risk, lower future time perspective, and lower generalized self-efficacy (all at p < 0.001). Higher generalized self-efficacy was related to increased physical activity ( p < 0.010). Higher future time perspective ( p < 0.001) and generalized self-efficacy ( p = 0.48) were associated with lower AD risk score. Subjective cognitive decline (SCD) was associated with lower self-efficacy, ability to delay gratification, and a less expansive future time perspective. Conclusions: Greater self-efficacy and perceived future time remaining were associated with lower AD risk and greater engagement in physical activity. SCD was associated with health beliefs that may negatively affect engagement in positive brain health behaviors. Assessment of and psychoeducation about these intrapersonal health belief constructs may be important targets for behavioral interventions to reduce AD risk.

19 July 2024 in Current Geriatrics Reports
Verified
Journal Article
Closed access
PDF file
VSVictoria Sanborn
Victoria Sanborn
JDJennifer D. Davis
Jennifer D. Davis
LKLaura Korthauer
Laura Korthauer

1 September 2020 in Neuropsychology
Verified
Journal Article
Closed access
LKLaura Korthauer
Laura Korthauer
WHWilliam C. Heindel
William C. Heindel
LLLeslie Y. Lai
Leslie Y. Lai
GTGeoffrey Tremont
Geoffrey Tremont
BOBrian R. Ott
Brian R. Ott
EFElena Festa
Elena Festa
Accessing semantic representations of real-world objects requires integration of multimodal perceptual features that are represented across relevant neocortical areas. Early Alzheimer's disease (AD) neuropathology, including neurofibrillary tangles in the perirhinal cortex as well as disrupted cortico-cortical connectivity, would be expected to disrupt the integration of object features. This integration deficit may underlie AD patients' semantic memory deficits and would be predicted to be more prominent for living objects, which tend to be more defined by sensory features compared with nonliving objects. Two experiments were conducted to assess feature integration in cognitively healthy older adults and patients with amnestic mild cognitive impairment (MCI). In both experiments, pictures of real-world objects were presented in congruent or incongruent colors. Participants were instructed to make a speeded color congruency judgment (Experiment 1) or name the presented surface color (Experiment 2). Across experiments, MCI patients showed a selective integration deficit for living, but not nonliving, objects across both experimental paradigms that was consistent with a deterioration in semantic structural representations rather than a deficit in controlled semantic retrieval. Planned secondary analyses with a subset of patients (Experiment 1) for whom PET imaging was available indicated that the degree of impairment was associated with the magnitude of cortical amyloid burden. These findings suggest that early AD pathology leads to impaired integration of distributed semantic object representations. The development of integration tasks as sensitive markers of early AD pathology may lead to more effective diagnostic tools for early detection and intervention. (PsycInfo Database Record (c) 2020 APA, all rights reserved).